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Despite the high level of interest in the use of machine learning 
(ML) and neuroimaging to detect psychosis at the individual 
level, the reliability of the findings is unclear due to potential 
methodological issues that may have inflated the existing lit-
erature. This study aimed to elucidate the extent to which the 
application of ML to neuroanatomical data allows detec-
tion of first episode psychosis (FEP), while putting in place 
methodological precautions to avoid overoptimistic results. 
We tested both traditional ML and an emerging approach 
known as deep learning (DL) using 3 feature sets of interest: 
(1) surface-based regional volumes and cortical thickness, 
(2) voxel-based gray matter volume (GMV) and (3) voxel-
based cortical thickness (VBCT). To assess the reliability of 
the findings, we repeated all analyses in 5 independent data-
sets, totaling 956 participants (514 FEP and 444 within-site 
matched controls). The performance was assessed via nested 
cross-validation (CV) and cross-site CV. Accuracies ranged 
from 50% to 70% for surfaced-based features; from 50% 
to 63% for GMV; and from 51% to 68% for VBCT. The 
best accuracies (70%) were achieved when DL was applied 
to surface-based features; however, these models generalized 
poorly to other sites. Findings from this study suggest that, 
when methodological precautions are adopted to avoid over-
optimistic results, detection of individuals in the early stages 
of psychosis is more challenging than originally thought. In 
light of this, we argue that the current evidence for the diag-
nostic value of ML and structural neuroimaging should be 
reconsidered toward a more cautious interpretation.
Key words:  multivariate pattern recognition/classification/ 
psychosis/neuroimaging/multi-site
Introduction
Over the last 3 decades, traditional mass-univariate neu-
roimaging approaches have revealed neuroanatomical 
abnormalities in individuals with psychosis.1–5 Because 
these abnormalities were detected using group-level 
inferences, it has not been possible to use this informa-
tion to make diagnostic and treatment decisions about 
individual patients. Machine learning (ML) is an area of 
artificial intelligence that promises to overcome this issue 
by learning meaningful patterns from the imaging data 
and using this information to make predictions about 
unseen individuals.6 Several ML studies have attempted 
to use neuroanatomical data to distinguish patients with 
established schizophrenia from healthy individuals, with 
promising results.7–10 At present, however, there are two 
important limitations in the existing literature that limit 
the translational applicability of the findings in real-
world clinical practice. First, given the well-established 
effects of illness chronicity and antipsychotic medica-
tion on brain structure,11–15 it is unclear to what extent 
classification was based on neuroanatomical changes 
associated with these factors rather than the onset of the 
illness per se. Consistent with this, both disease-stage and 
antipsychotic medication were identified as significant 
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moderators in a recent meta-analysis of diagnostic bio-
markers in schizophrenia.7 Also in line with this, Pinaya 
et al16 reported that the same ML model that was able to 
distinguish between patients with established schizophre-
nia and healthy controls (HCs) with an accuracy of 74% 
showed poor generalizability (56%) when applied to a 
cohort of individuals with first episode psychosis (FEP). 
Taken collectively, these findings suggest that represen-
tations learned from patients with established schizo-
phrenia may not be applicable to individuals with a first 
episode of the illness. Second, the clinical utility of any 
ML-based diagnostic tool for detecting patients with an 
established illness is likely to be very limited; in contrast, 
detecting the initial stages of an illness, when diagnosis 
may be uncertain and treatment is yet to be decided, is 
likely to have much greater clinical utility.
So far only a limited number of  studies have applied 
ML to neuroanatomical data in the initial stages of  the 
illness when the effects of  illness chronicity and anti-
psychotic medication are minimal. These studies have 
produced inconsistent results, including poor (eg, 51% 
in Winterburn et  al17), modest (eg, 63% in Pettersson-
Yeo et al18), and good (eg, 86% in Borgwardt et al19 or 
85% in Xiao et al20) accuracies. There are a number of 
possible reasons for such inconsistency. First, most of 
the studies used small samples (N ≤50) (see Kambeitz 
et  al7 for a meta-analysis), which have been shown to 
yield unstable results.21,22 Second, the vast majority of 
studies used data from a single site, and as such may 
have generated results that were specific to the charac-
teristic of  the local sample rather than the illness per 
se. Third, a series of  recent articles have highlighted 
potential methodological issues that may have caused 
inflated results in some of  the published studies.9,17,22–25 
These issues include, eg, (1) failure to use a nested cross-
validation (CV) framework to avoid knowledge-leakage 
between training and test sets; (2) failure to perform fea-
ture transformation and/or selection within a rigorous 
CV framework resulting in so-called “double dipping”; 
(3) publication bias leading to an overrepresentation of 
positive findings, especially in studies with small sam-
ples and (4) failure to test performance on additional 
independent samples. Also, we note that all studies have 
employed traditional “shallow” ML techniques, such 
as support vector machine and logistic regression. The 
intuitiveness of  such techniques has made them very 
popular in neuroimaging studies of  psychiatric and neu-
rological disease. Deep learning (DL) is an alternative 
type of  ML, which has been gaining considerable atten-
tion in clinical neuroimaging.9,16,23,26 Contrary to tradi-
tional ML, where the immediate input data are used to 
extract patterns (hence the term “shallow”), DL learns 
complex latent features of  brain structure through con-
secutive nonlinear transformations (hence the term 
“deep”), which are then used for classification. Given its 
ability to learn more intricate and abstract patterns, DL 
might be particularly suitable to detect the subtle and 
heterogeneous neuroanatomical abnormalities charac-
teristic of  the early stages of  psychosis.1,27,28
This study aims to elucidate the extent to which the 
application of  ML to neuroanatomical data allows 
distinction between patients with FEP and HCs at the 
individual level. To overcome the limitations of  previ-
ous studies, we used a total of  5 datasets from different 
sites, each with a sample size above the recommended 
threshold for a stable performance,21 and employed both 
shallow and deep ML techniques. In addition, following 
a series of  recent articles highlighting potential method-
ological issues in the existing literature,9,17,22–25 we put in 
place a series of  precautions to minimize the risk of  over-
fitting. On the basis of  previous studies, we hypothesize 
that (1) FEP and HC will be classified with statistically 
significant performances ranging between 70% and 80%7 
and (2) DL will perform better than traditional shallow 
approaches.26
Methods
Subjects
Participants were recruited as part as 5 independent stud-
ies carried out in multiple sites, all of which have been 
previously published:
- Site 1: Chengdu, China29
- Site 2: London, England (Genetic and Psychosis 
study30)
- Sites 3 and 4: Santander A  and B, Spain (Programa 
Asistencial Fases Iniciales de Psicosis (First Episode 
Psychosis Clinical Program) study31)
- Site 5: Utrecht, The Netherlands (Genetic Risk and 
Outcome of Psychosis study32)
All patients were experiencing their first psychotic epi-
sode, defined as the first manifestation of psychotic 
symptoms meeting criteria for a psychotic disorder, as 
specified by the DSM-IV33 or ICD-1034. The demographic 
and clinical characteristics, including duration of illness, 
are reported in table 1. For information on recruitment 
criteria, see supplementary material.
MRI Data Acquisition and Preprocessing
High-resolution three-dimensional T1-weighted images 
were acquired independently at each site (supplementary 
table 2). From each image, 3 types of data features were 
extracted (see supplementary material):
- Voxel-based gray matter volume (GMV): whole-brain 
voxel-wise estimate of the local density of gray matter 
(GM) in a given voxel region35
- Voxel-based cortical thickness (VBCT): cortical thick-
ness maps in which each voxel in the GM is assigned a 
thickness value36,37
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- Surfaced-based regional volumes and cortical thick-
ness: volume and thickness of predefined cortical and 
subcortical regions extracted with FreeSurfer38
Statistical Analysis
Demographic and Clinical Variables. Differences in age, 
gender, and total intracranial volume between FEP and 
HCs were examined using an independent-samples t-test 
and chi-square test, as implemented in the Statistical 
Package for the Social Sciences 24.0 (SPSS 24.0).
Group-Level Comparisons. For completeness, a standard 
group-level analysis was also carried out for each site 
and type of feature set separately. See supplementary 
material sections 1.4.1. and 2.1 for methods and results, 
respectively.
Multivariate Pattern Recognition Analysis. Dimensionality 
Reduction: Principal Component Analysis Principal 
component analysis (PCA) was used to reduce the num-
ber of voxels of the GMV and VBCT maps (see supple-
mentary material).
Classifiers Four methods were used for classification: 
k-nearest neighbors (KNN), logistic regression (LR), 
support vector machine (SVM) and deep neural networks 
(DNN) (see supplementary material). These methods 
were chosen based on their increasing order of complex-
ity (KNN is a straightforward algorithm, whereas DL 
can be more powerful at the expense of transparency), 
popularity (SVM and LR are among the most ML tech-
niques used in previous studies), and novelty (DL has 
yielded promising results in psychiatric neuroimaging but 
is yet to be applied to FEP) (figure 1).
KNN: non-parametric method that uses the distance 
between data points to make new predictions by assign-
ing unseen data to the same class to which the closest 
data points belong to39.
LR: regression model applied to one dependent cat-
egorical variable implemented via elastic net, a regular-
ized regression that combines the regularizations L1 and 
L2 penalties of Least Absolute Shrinkage and Selection 
Operator (LASSO) and ridge regression, respectively, to 
avoid overfitting.40
SVM: method that estimates a hyperplane with an 
optimum margin that best separates two classes, deter-
mined by the maximum distance from any data point. 
Once defined, this hyperplane is used to classify unseen 
data.41,42
DNN: multi-layered fully connected networks in which 
higher-level features are learned as a nonlinear combina-
tion of lower-level features, allowing the extraction of 
complex and abstract patterns.43
Model Training and Testing
Within-site classification. All models were assessed through 
a nested 10-fold stratified CV framework  (figure  2) to 
ensure that the data for hyperparameter tuning and 
Fig. 1. Three features were extracted from each image: GMV, VBCT, and FreeSurfer surface-based regional volumes and cortical 
thickness. The dimensionality of GMV and VBCT was reduced through PCA. The resulting features were analyzed with four classifiers: 
(a) SVM, (b) LR, (c) KNN and (d) DNN. GMV, gray matter volume; VBCT, voxel-based cortical thickness; PCA, principal component 
analysis; SVM, support vector machine; KNN, k-nearest neighbors; LR, logistic regression; DNN, deep neural network.
D
ow
nloaded from
 https://academ
ic.oup.com
/schizophreniabulletin/advance-article-abstract/doi/10.1093/schbul/sby189/5365736 by King's C
ollege London user on 27 February 2019
Page 5 of 10
Using ML and Structural Neuroimaging to Detect FEP
Fig. 2. Schematic representation of nested CV. Nested CV involves a secondary inner CV loop using the training data from the 
primary outer CV split, where different sets of hyperparameters are tested (eg, different values for the C parameter for SVM). The best-
performing hyperparameters among the 10 inner folds are then used to train a model in the whole training set defined by the outer loop. 
This model is then tested using the test set of the outer loop. The final performance is estimated by averaging accuracies in the test set 
across all 10 outer folds. CV, cross-validation; SVM, support vector machine.
the data to test the algorithm were strictly independent. 
A  10-fold CV was chosen as a trade-off between bias, 
variance, and the demanding computational resources 
required to run DNN.
Cross-site classification. The best site-level model was 
further tested in each one of the remaining independent 
samples. All 10 instances trained during the CV were 
used to classify the participants from all the remaining 
sites separately. The resulting ensemble of models pre-
dicted the class of each participant using the soft voting 
method, where the class label was defined by the average 
of the 10 predicted probabilities.
Performance Measures Balanced accuracy, sensitivity, 
and specificity were chosen as the performance metrics. 
Statistical significance of the balanced accuracy was 
determined by permutation testing with 1000 permuta-
tions (see supplementary material).
Effect of  Antipsychotic Medication and Psychotic 
Symptoms To examine whether antipsychotic medica-
tion or psychotic symptoms contributed to the classifiers’ 
performance, chlorpromazine equivalents and positive 
and negative psychotic symptoms were regressed against 
the predicted labels using an logistic regression (see sup-
plementary material for details).
Results
Sociodemographic and Clinical Parameters
No statistically significant differences were identified 
between patients and controls for age, gender, or total 
GMV at each site (table 1).
Single-Subject Classification
Can We Detect FEP at the Individual Level? Balanced 
accuracy, sensitivity, specificity, and statistical signifi-
cance for each feature set of  interest and site are pre-
sented in table 2 (for a visual display of  the accuracies 
and standard deviations see supplementary figure  3 
in the supplementary material). Overall, results were 
poor to modest across all types of  feature sets and sites, 
although the site with the smallest sample size (site 
2)  showed the lowest performance consistently across 
all feature sets. Overall, regression analyses examining 
the effect of  antipsychotic medication and psychotic 
symptoms on the performance of  each classifier did not 
show a significant effect (see supplementary material).
What Are the Most Effective Type of Feature Set? There 
was no clear effect of type of feature set across sites. 
However, it can be seen that surface-based regional data 
tended to yield higher accuracies, especially when ana-
lyzed with DNN.
Can We Generalize the Results From One Site to the Others? 
The best performances were achieved by two DNN models 
at sites 1 and 3 using regional volumes and cortical thick-
ness, with 70.5% and 70.2%, respectively. However, both 
models generalized poorly when tested on the remaining 
sites: specifically, the DNN model from site 1 achieved 
accuracies (sensitivity/specificity) of 52.1% (56.3%/47.9%), 
61.1% (70.0%/52.7%), 52.1% (65.7%/38.6%), and 50.0% 
(48.3%/51.7%) when applied to sites 2 through 5, respec-
tively; whereas the DNN model from site 3 achieved accu-
racies of 52.2% (96.5%/8.4%), 49.2% (83.5%/33.4%), 55.1% 
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(70.1%/40.0%), and 51.0% (67.5%/34.6%) when applied to 
sites 1, 2, 4 and 5, respectively. To examine the possibility 
that poor generalizability was due to site differences, the 
same DNN model was applied to the total data with the 5 
sites added as additional features. Features weights were then 
investigated to determine the importance of site. Results 
showed that out of the 174 features, the weights for site 1, 
2, 3, 4, and 5 ranked 110, 150, 108, 71, and 112, respectively.
Discussion
In the last few years, there has been increasing inter-
est in the translational potential of  ML approaches in 
psychosis. As the field matures, there is emerging skep-
ticism about replicability and generalizability, which 
has led to recent calls for greater caution in the inter-
pretation of  the findings.9,17,22,23,25 This study aimed to 
elucidate the extent to which the application of  ML 
to neuroanatomical data allows detection of  individ-
uals at the early stages of  psychosis when the effects 
of  illness chronicity and antipsychotic medication are 
minimal. To overcome the limitations of  the existing 
literature, we used 5 independent datasets and put in 
place a series of  methodological precautions to avoid 
overoptimistic results. Contrary to expectation, the 
performances of  all methodological approaches tested 
were poor to modest across all sites. Later we discuss 
some of  the main aspects that emerge from our inves-
tigation, including sample size, full independence of 
training and test data, cross-site generalizability, and 
testing multiple pipelines. We conclude the discussion 
by considering possible future directions.
Sample Size, Homogeneity, and Publication Bias
A possible explanation for why our accuracies are lower 
than those reported in the existing literature is that some 
of the previous studies may have reported overoptimistic 
results due to the use of fairly small sample sizes. To illus-
trate this possibility, we tested for an association between 
sample size and classification accuracy across studies 
using ML and structural MRI (sMRI) in the existing lit-
erature (see supplementary material). Unsurprisingly, we 
found a moderate negative association for studies that 
examined established schizophrenia (r = −.41) and FEP 
(r = −.59; after excluding Xiao et al,20 which was a clear 
outlier; figure 3A). This is consistent with the notion that 
some of the previous studies may have reported overopti-
mistic accuracies due to the use of inadequate sample size.
There are at least two possible ways in which inade-
quate sample size can lead to an inflated estimation of the 
accuracy of an algorithm, including sample homogene-
ity and publication bias.22,25 First, smaller samples tend to 
be more homogeneous, making it easier for an algorithm 
to learn shared abnormalities in patients relative to con-
trols and resulting in higher accuracies. In contrast, larger 
samples tend to be more heterogeneous due to the loosen-
ing of inclusion criteria; in this case, it may be more chal-
lenging to find a shared pattern of abnormalities resulting 
in lower performances. This inverse relationship between 
Table 2. Accuracies (Sensitivity/Specificity) for Each Feature Set and Algorithm Across All Sites Using Nested 10-fold Stratified Cross-
Validation. The Classifier Yielding the Best Balanced Accuracy Is Highlighted in Bold for Each Site
  Regional volumes and cortical thickness GMV VBCT
Site 1
Chengdu, China
KNN 60.7** (74.3/47.1) 60.7** (49.5/71.9) 62.1** (72.1/52.1)
LR 61.9** (64.9/58.9) 60.1** (62.9/58.6) 67.2** (65.8/68.5)
SVM 61.3** (66.4/56.2) 60.7** (63.0/58.5) 52.7* (24.6/97.3)
DNN 70.5** (72.2/68.8) 57.7** (59.5/56.0) 66.4** (63.9/68.3)
Site 2
London, England
KNN 56.7 (50.9/62.5) 43.9 (33.6/54.3) 53.5 (38.4/68.6)
LR 51.6 (45.0/58.2) 51.9 (53.8/50.0) 61.6** (63.2/60.0)
SVM 45.9 (49.3/42.5) 53.9 (53.4/54.3) 51.0 (96.3/5.7)
DNN 58.8* (49.5/68.0) 40.8 (47.4/34.3) 53.4 (52.4/55.3)
Site 3
Santander A, Spain
KNN 59.6** (45.5/73.6) 50.5 (31.8/69.1) 58.0* (50.0/66.4)
LR 58.6* (58.2/59.1) 63.2** (63.6/62.7) 59.1* (58.2/60.0)
SVM 60.5** (61.8/59.1) 65.9** (68.2/63.6) 51.8* (90.9/12.7)
DNN 70.2** (70.0/70.4) 50.2 (52.7/63.6) 59.6 (60.0/59.1)
Site 4
Santander B, Spain
KNN 56.6* (91.8/21.4) 58.9** (70.7/47.1) 59.5* (67.7/51.1)
LR 54.8 (73.9/35.7) 59.6** (57.8/61.4) 62.6** (56.8/62.4)
SVM 56.0 (65.0/47.1) 57.4* (71.9/42.9) 58.4* (71.9/52.9)
DNN 62.0** (76.8/47.1) 59.3* (81.4/37.1) 58.8** (62.4/53.1)
Site 5
Utrecht, The Netherlands
KNN 52.7 (53.6/51.8) 54.5 (33.8/75.3) 52.2 (36.5/67.9)
LR 58.5* (61.7/55.4) 61.3** (56.8/65.7) 60.5** (60.6/60.4)
SVM 60.7** (59.7/61.7) 62.4** (63.1/61.8) 56.3 (51.2/61.4)
DNN 54.9 (59.2/51.8) 58.0** (58.1/57.9) 60.1** (56.1/64.2)
Note: SVM, support vector machine; LR, logistic regression, KNN, k-nearest neighbors; DNN, deep neural network; GMV, voxel-based 
gray matter volume; VBCT, voxel-based cortical thickness.
*P < .05; **P < .01.
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sample size and accuracy was not observed in our inves-
tigation; however, this might be explained by the fact that 
there was not sufficient variability in sample size across 
our five datasets. Second, smaller samples tend to be 
unstable and thus yield underestimated as well as overes-
timated accuracies.21,44 This may, in turn, lead to publica-
tion bias, with overestimated accuracies being more likely 
to be published. In their meta-analysis of ML studies of 
schizophrenia, Kambeitz et al7 reported that no publica-
tion bias was evident when all studies—including sMRI, 
functional magnetic resonance imaging, and DTI—were 
examined together. To test for publication bias in sMRI 
studies, we repeated the same statistical analysis focus-
ing on this modality (see supplementary material). This 
revealed a statistically significant asymmetry in the fun-
nel plot of published studies, indicating the presence of 
publication bias (figure 3B). This is in line with emerging 
concerns about possible overrepresentation of inflated 
performances in the literature.17,22,23,25
Full Independence of Training and Testing Set Data
Following recent recommendations on how to overcome 
methodological issues that may have led to initial inflated 
results,9,23,25 we adopted two important methodological 
precautions. First, the use of simple CV, in which the same 
test data are used to both tune model hyperparameters and 
evaluate its performance, has been criticized as it almost 
certainly leads to inflated performances.45,46 In the pres-
ent investigation, algorithms were trained and tested via 
nested CV. This ensured that the test set remained fully 
independent from the training set, with only the latter being 
used to optimize model parameters. Second, implementing 
feature selection in a 2-step approach, where, eg, univariate 
tests (eg, t-test) are applied in the whole sample and only 
the statistically significant features are used for classifica-
tion, is likely to result in overoptimistic performances as 
features are chosen based their performance on data that 
should be completely independent for testing the classifier. 
In the present investigation, therefore, transformations 
to the data, such as feature selection, were implemented 
within the CV framework, ie, parameters were derived 
from the training data only and subsequently applied to 
the test set. The adoption of these methodological precau-
tions, aimed at ensuring full independence between train-
ing and test data, might explain the fact that accuracies in 
the present investigation were lower than expected.
Cross-Site Generalizability
The use of independent samples to develop and validate 
an algorithm is a critical requirement if  the ultimate 
aim is to develop flexible ML-based tools that could be 
used in a clinical setting.23,25 However, only a minority of 
studies have attempted to do this, eg,22,47,48, and most of 
them have reported considerably lower performances in 
the independent sample. In the present investigation, the 
highest accuracies—obtained using specific combinations 
of dataset, type of feature set and algorithm—were 70% 
(in sites 1 and 3 with surface-based regional features and 
DNN); this performance would appear to be in line with 
previous similar studies. However, selectively reporting 
Fig. 3. (A) Accuracy of diagnostic sMRI ML studies over time and sample size (circle increases with sample size). From the first study 
until 2015, the vast majority of studies reported accuracies ranging between 70% and 100%; from 2016, however, performances have 
dropped overall with accuracies ranging between chance-level and 85%. (B) Funnel plot for sMRI studies in schizophrenia and FEP 
showing the distribution of individual studies according to their sample size (1/√ESS) and effect size (log diagnostic odds ratio). The plot 
revealed statistically significant asymmetric distribution around the main effect of sMRI studies (P = .013), indicating a bias favoring 
higher effect sizes. sMRI, structural MRI; ML, machine learning; FEP, first episode psychosis.
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these accuracies from our wider set of results would have 
portrayed a distorted picture of the potential of ML to 
detect the initial stages of psychosis at the individual 
level.24 This is especially true since after testing these 
two models in independent datasets, their performance 
did not hold up, indicating low cross-site generalizabil-
ity. Such low cross-site generalizability could be due to 
site-related differences in scanning parameters, cultural 
interpretation of diagnostic criteria, and ethnicity; there-
fore, it might be possible to achieve higher cross-site gen-
eralizability by combining samples that are homogenous 
with respect to these variables. Nevertheless, our current 
results indicate that algorithms developed using data 
from a specific centre do not perform well when applied 
to data from other centers, and thus have limited clinical 
applicability.
Testing Multiple Pipelines
Because existing studies tend to differ with respect to 
several methodological aspects, at present, it is difficult 
to say which pipeline is optimal for detecting FEP.47 
Multi-pipeline studies have therefore been proposed as 
a useful way to disentangle what aspects works best.23 
Importantly, this approach may also help build more 
generalizable models, as the development of a bespoke, 
and possibility overfitted, pipeline to a local sample is 
less likely to occur. Consistent with this, Salvador et al47 
tested the performance of a range of ML approaches 
in different types anatomical features extracted from 
patients with schizophrenia and controls, and reported 
lower accuracies (66%–68%) compared to previous simi-
lar studies using a single pipeline. Winterburn et  al17 
also used multiple pipelines in FEP and reported poor 
to modest accuracies, ranging from 51% to 73%. Taken 
collectively, evidence from these studies, including our 
own, suggest that when features are not manually carved 
to fit one algorithm applied to one specific small dataset, 
performance tends to drop. This can be seen in figure 3A 
where two generations of studies emerge: initially, there 
were mostly small single-site, single-feature, and single-
algorithm high-performance studies; more recently the 
use of (1) larger samples,16,47,20,54 (2) multicentre stud-
ies,48,49 (3) assessment of different algorithms and/or fea-
tures in one/several site(s),17,47 or (4) independent sample 
testing48,49 are reshaping the original, and possibly overin-
flated, enthusiasm with more realistic performances.
What Next for ML-sMRI Studies of Psychiatric 
Disease?
Unlike group-level analysis, where larger samples lead to 
increased chance of  detecting a statistically significant 
result (even with a small effect size), in ML larger sam-
ples do not necessarily equate to better results; instead, 
these tend to lead to lower accuracies due to increased 
heterogeneity.22,28 Despite this challenge, larger samples 
are likely to be more representative of  the illness, less 
likely to overfit and thus carry more translational poten-
tial. Future ML studies will have to address this issue 
to overcome the increasingly apparent bottleneck in the 
performance that is arising with larger sample sizes (fig-
ure 3A). A possible way of  doing so could be to use nor-
mative models, where an individual is mapped against a 
normative model that should encompass the heterogene-
ity characteristic of  the normal population. Here, illness 
is considered an extreme case within a normal range, 
which is likely to be a more ecologically valid approach 
than the traditional case–control paradigm.50,51
Greater methodological standardization based on 
“good-practice recommendations” could also help dis-
entangle the current conflicting evidence. For example, 
guidelines for minimum sample size such as the thresh-
old (n > 130) proposed by Nieuwenhuis et al21 are a good 
start. The need for independent sample testing has also 
been widely acknowledged as an essential step toward 
generalizability23,25; however, even the most recent stud-
ies do not always perform this. Moving forward, this 
type of  generalizability test is likely to become a gold 
standard for ML diagnostic studies. More transparency 
in the implementation of  ML is also needed. Several 
studies do not provide enough information about how 
the algorithm was trained and tested.23,28,52 This hinders 
a thorough assessment of  the validity of  the study as well 
as its replicability. Finally, it should be noted that, even if  
sMRI was able to distinguish between patients with FEP 
and disease-free individuals with high levels of  accuracy, 
this would be of  limited clinical utility. This is because, 
from a clinical translation perspective, the real challenge 
is not to distinguish between patients and disease-free 
individuals, but to develop biological tests that could be 
used to choose between alternative diagnoses and opti-
mize treatment.52
Conclusion
The present investigation attempted to overcome the 
limitations of the existing literature using a number of 
strategies. First, we studied patients with FEP in which 
the effects of antipsychotic medication and illness chro-
nicity are likely to be minimal. Second, the sample size 
of each of our 5 datasets was greater than the recom-
mended threshold for achieving a stable performance in 
ML–sMRI studies.21 Third, critical methodological pre-
cautions (eg, nested CV and appropriate use of feature 
selection) were adopted to ensure an unbiased assess-
ment of performance. Fourth, we systematically assessed 
the performance of a range of algorithms and features 
across several datasets, thereby minimizing the possibil-
ity of developing a bespoke and likely overfitted model 
to a single site. Fifth, we assessed the cross-site general-
izability of the best models at the single-site level. Our 
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findings suggest that the use of ML and sMRI allows 
detection of FEP at the individual level with relatively 
modest accuracies—lower than what was expected based 
on previous studies and much lower than what would be 
required for clinical translation. We speculate that some 
of the previous results may have been over-optimistic due 
to a combination of small sample sizes, less-than-rigor-
ous methodologies, and possible publication bias and 
argue that the current evidence for the diagnostic value of 
ML and structural neuroimaging should be reconsidered 
toward a more cautious interpretation.
Over the past few years, the number of ML studies in 
psychosis has been increasing rapidly.52 As larger samples 
and more powerful computational resources become 
available, this momentum is likely to continue to grow 
over the coming years.53 Therefore, it is important for the 
research community to be aware of the challenges and 
limitations of applying ML to psychosis   such as the 
several potential “distortion” of the findings along the 
ML pipeline, as discussed in a recent review.52 In light 
of these challenges and limitations, the extent to which 
the application of ML in psychosis will lead to a more 
valid construct of the illness remains an open question. 
We encourage researchers to continue pursuing the inte-
gration of ML and neuroimaging, while exercising cau-
tion to avoid inflated results and ultimately a distorted 
view of the potential of this approach in psychiatric 
neuroimaging.
Supplementary Material
Supplementary data are available at Schizophrenia 
Bulletin online.
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